Curium Pharma
France - Paris
DiagnosticsFocus: Nuclear Diagnostics & Medicine
Curium Pharma is a life sciences company focused on Nuclear Diagnostics & Medicine.
Hematology
Open Jobs
0
Products & Portfolio (15)
6 discontinued products not shown
DETECTNET
copper cu 64 dotatate
Peak
INTRAVENOUS · SOLUTION
Positron Emitting Activity
2020
0
GALLIUM CITRATE GA 67
gallium citrate ga-67
LOE Approaching
INJECTION · INJECTABLE
CLINICAL PHARMACOLOGY Gallium Citrate Ga 67, with no carrier added, has been found to concentrate in certain viable primary and metastatic tumors as well as focal sites of infection. The mechanism of concentration is unknown, but investigational studies have shown that gallium Ga-67 accumulates in lysosomes and is bound to a soluble intracellular protein. It has been reported in the scientific literature that following intravenous injection, the highest tissue concentration of gallium Ga-67 - other than tumors and sites of infection - is the renal cortex. After the first day, the maximum concentration shifts to bone and lymph nodes and after the first week, to liver and spleen. Gallium Ga-67 is excreted relatively slowly from the body. The average whole body retention is 65 percent after seven days, with 26 percent having been excreted in the urine and 9 percent in the stools.
1979
30
IOFLUPANE I-123
ioflupane i-123
Post-LOE
INTRAVENOUS · SOLUTION
Radiopharmaceutical Activity
2022
30
OCTREOSCAN
indium in -111 pentetreotide
LOE Approaching
PeptideINJECTION · INJECTABLE
CLINICAL PHARMACOLOGY General Pentetreotide is a DTPA conjugate of octreotide, which is a long-acting analog of the human hormone, somatostatin. Indium In 111 pentetreotide binds to somatostatin receptors on cell surfaces throughout the body. Within an hour of injection, most of the dose of indium In 111 pentetreotide distributes from plasma to extravascular body tissues and concentrates in tumors containing a high density of somatostatin receptors. After background clearance, visualization of somatostatin receptor-rich tissue is achieved. In addition to somatostatin receptor-rich tumors, the normal pituitary gland, thyroid gland, liver, spleen and urinary bladder also are visualized in most patients, as is the bowel, to a lesser extent. Excretion is almost exclusively via the kidneys. Pharmacokinetics Radioactivity leaves the plasma rapidly; one third of the radioactive injected dose remains in the blood pool at 10 minutes after administration. Plasma levels continue to decline so that by 20 hours post-injection, about 1% of the radioactive dose is found in the blood pool. The biological half-life of indium In 111 pentetreotide is 6 hours. Half of the injected dose is recoverable in urine within 6 hours after injection, 85% is recovered in the first 24 hours, and over 90% is recovered in urine by two days. Hepatobiliary excretion represents a minor route of elimination, and less than 2% of the injected dose is recovered in feces within three days after injection. Metabolism For several hours after administration, plasma radioactivity is predominantly in parent form. Ten percent of the radioactivity excreted is nonpeptide-bound. Pharmacodynamics Indium In 111 pentetreotide binds to cell surface receptors for somatostatin. In nonclinical pharmacologic studies, the hormonal effect of Octreoscan in vitro is one-tenth that of octreotide. Since diagnostic imaging doses of indium In 111 pentetreotide are lower than the therapeutic doses of octreotide, indium In 111 pentetreotide is not expected to exert clinically significant somatostatin effects. Indium In 111 pentetreotide is cleared from the body primarily by renal excretion. Indium In 111 pentetreotide elimination has not been studied in anephric patients or in those with poorly functioning kidneys. It is not known whether indium In 111 pentetreotide can be removed by dialysis. Dosage adjustments in patients with decreased renal function have not been studied. Clinical Trials Octreoscan was studied in nine unblinded clinical studies in a total of 365 patients. Of these patients, 174 were male and 191 were female. Their mean age was 54.0 years (range 1.8 to 86 years). One patient was under the age of 2 and 2 patients were between the ages of 2 and 12; 223 patients (61.1%) were between 18 and 60 years; and 136 patients (37.3%) were older than 60 years. A racial distribution is not available. Eligible patients had a demonstrated or high clinical suspicion of a neuroendocrine tumor. The most common tum
1994
30
SODIUM IODIDE I 123
sodium iodide i 123
Post-LOE
ORAL · CAPSULE
1989
30
SODIUM IODIDE I 123
sodium iodide i 123
Post-LOE
ORAL · CAPSULE
1989
30
TECHNESCAN HDP
technetium tc 99m oxidronate
LOE Approaching
INJECTION · INJECTABLE
1981
30
TECHNESCAN MAG3
technescan tc 99m mertiatide
LOE Approaching
PeptideINJECTION · INJECTABLE
1990
30
TECHNESCAN PYP KIT
technetium tc 99m pyrophosphate
LOE Approaching
INJECTION · INJECTABLE
1974
30
TECHNETIUM TC 99M SESTAMIBI
technetium tc 99m sestamibi
Post-LOE
INJECTION · INJECTABLE
2008
30
TECHNETIUM TC-99M PENTETATE KIT
kit for the preparation of technetium tc 99m pentetate
Post-LOE
INJECTION · INJECTABLE
Lead Chelating Activity
2025
30
THALLOUS CHLORIDE TL 201
thallous chloride, tl 201
LOE Approaching
INJECTION · INJECTABLE
1979
30
Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Founded: 2017
Portfolio: 21 approved products
Top TAs: Hematology
Portfolio Health
Peak1 (5%)
LOE Approaching14 (67%)
Post-LOE6 (29%)
21 total products